estimate the sensitivity of the HMP test in identifying visual field functional defects in subjects with CNV secondary to AMD

The HMP device is intended to aid patients in identifying their visual abnormalities and in addition to their own symptoms or Amsler grid use and aid in their prompt referral to eye care professional examination so clinical diagnosis can be made. As such the goal of the clinical plan is to demonstrate that patients who have CNV do demonstrate visual field abnormalities when tested with the HMP

Inclusion Criteria:

• Capable and willing to sign a consent form and participate in the study
• subjects with AMD related lesions: New onset (up to 60 days) non-treated CNV
• Age >50 years
• VA with habitual correction >20/200 in study eye
• Familiar with computer usage

Exclusion Criteria:

• Evidence of macular disease other than AMD or glaucoma in the study eye
• Presence of any significant media opacity that precludes a clear view of the macular area as identified in the study eye by biomicroscopy, CFP, or FA
• Any non-macular related ocular surgery performed within 3 months prior to study entry in the targeted eye
• Inability to tolerate intravenous FA
• Participation in another study with the exclusion of AREDS study

62 completed subjects with new choroidal neovascularization AMD in at least one eye